Treatment modalities and survival outcomes in patients with hepatocellular carcinoma with brain metastases (HCC-BM): A large national study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Effects of lack of access to cancer medication on survival of patients with lung cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...

In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...

In a recent study published in The Lancet Regional Health-Southeast Asia, researchers developed an artificial intelligence (AI)-based predictive system (AIPS) model for the early detection of lung ...

VIENNA — For patients with non-small cell lung cancer (NSCLC) carrying the specific T790M mutation in the epidermal growth factor receptor (EGFR) gene, there is now a new standard of care, say experts ...

Background: Treatment options for lung cancer patients with epidermal growth factor receptor (EGFR) mutations are limited after tyrosine kinase inhibitor (TKI) resistance. We aimed to evaluate the ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan showed a 42.7% objective response rate in previously treated patients Data support recent BLA submission in the U.S. for this patient population ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...